Co promote

Quote
























anonymous said:
Co-promote?
Click to expand...
Hint: Reproxalap for the treatment of signs and symtoms of dry eye diease made by Aldeyra Therapeutics. Its pending FDA approval by November 23, 2023. It will give Kowa reps advanced access and relationships in the ophthalmology offices for the Fuch's drug in their pipeline. Until then it can be promoted in the primary care setting for dry eye issues with diabetes and other disease states. There will be no co-promote, Kowa will buy the rights to market the drug from Aldeyra Therapeutics (they do not have a sales force). It's also a first in class drug. Reproxalap will dove tail nicely with Kowa's Fuch disease drug, if it get approved in about a 1-2 years.
 






anonymous said:
Hint: Reproxalap for the treatment of signs and symtoms of dry eye diease made by Aldeyra Therapeutics. It’s pending FDA approval by November 23, 2023. It will give Kowa reps advanced access and relationships in the ophthalmology offices for the Fuch's drug in their pipeline. Until then it can be promoted in the primary care setting for dry eye issues with diabetes and other disease states. There will be no co-promote, Kowa will buy the rights to market the drug from Aldeyra Therapeutics (they do not have a sales force). It's also a first in class drug. Reproxalap will dove tail nicely with Kowa's Fuch disease drug, if it get approved in about a 1-2 years.
Click to expand...

wow very informative! thank you!
 






anonymous said:
Hint: Reproxalap for the treatment of signs and symtoms of dry eye diease made by Aldeyra Therapeutics. It’s pending FDA approval by November 23, 2023. It will give Kowa reps advanced access and relationships in the ophthalmology offices for the Fuch's drug in their pipeline. Until then it can be promoted in the primary care setting for dry eye issues with diabetes and other disease states. There will be no co-promote, Kowa will buy the rights to market the drug from Aldeyra Therapeutics (they do not have a sales force). It's also a first in class drug. Reproxalap will dove tail nicely with Kowa's Fuch disease drug, if it get approved in about a 1-2 years.
Click to expand...
Interesting information, sounds right after a little research. Makes sense that there is no co-promote, what sane company would attach their wagon to Kowa after all the leadership failures and poor decisions over the last few years.
 






anonymous said:
Hint: Reproxalap for the treatment of signs and symtoms of dry eye diease made by Aldeyra Therapeutics. Its pending FDA approval by November 23, 2023. It will give Kowa reps advanced access and relationships in the ophthalmology offices for the Fuch's drug in their pipeline. Until then it can be promoted in the primary care setting for dry eye issues with diabetes and other disease states. There will be no co-promote, Kowa will buy the rights to market the drug from Aldeyra Therapeutics (they do not have a sales force). It's also a first in class drug. Reproxalap will dove tail nicely with Kowa's Fuch disease drug, if it get approved in about a 1-2 years.
Click to expand...

Lots of knowledge and a lot of wishing. Now reality. If this is the product it makes sense, but it pushes you into yet another specialty which are more spread out and are concentrated around population centers. The relationship thing is correct for the new Kowa product but how big are the sales teams in other Ophthalmology sales teams? 100? This is a good product if you do get it. You still have the brain trust in leadership and marketing doing the launch. The Fuchs disease product in 1-2 years? Not likley, more like 3-4 years. the sales force is bloated for this type of product and if Seglentis doesn't get better expect more downsizing.

Aldeyra Therapeutics: FDA accepts NDA for dry eye treatment (ophthalmologytimes.com)
 






You’re going down the wrong rabbit hole. It’s not an ophthalmology drug. When Kowa’s FD drug is ready, it will be marketed by a small specialty sales force with huge territories.
 






Top Bottom
Back
Quote